Sign In
Buy XOMA
$41.95
-0.0500 (-0.119%)
At Close: Jun 23, 2026
EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced that its Board of Directors has authorized the following
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders?
11:47am, Friday, 12'th Jun 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—TMHC, CZR, XOMA, and AVNS
04:16pm, Thursday, 11'th Jun 2026
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders an
Saying Goodbye To The XOMA Royalty PFDs
08:00am, Monday, 25'th May 2026
Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or
BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of X
XOMA Royalty (XOMA) Moves 10.7% Higher: Will This Strength Last?
06:56am, Tuesday, 28'th Apr 2026
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down th
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
03:06pm, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the propo
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
01:18pm, Monday, 27'th Apr 2026
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).
Are OGN, RMAX, XOMA, REAX Obtaining Fair Deals for their Shareholders?
11:24am, Monday, 27'th Apr 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders
10:00am, Monday, 27'th Apr 2026
MILWAUKEE, April 27, 2026 /PRNewswire/ -- Ademi LLP is investigating XOMA (NASDAQ: XOMA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per sha
Ligand Pharma to buy fellow biotech royalty rights buyer XOMA for $739 million
08:12am, Monday, 27'th Apr 2026
Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday.
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary por
XOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
03:43am, Wednesday, 08'th Apr 2026
XOMA Royalty Corporation (NASDAQ: XOMA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $29
